Metsera Inc. (NASDAQ:MTSR - Get Free Report) shot up 10.3% during mid-day trading on Wednesday . The company traded as high as $29.65 and last traded at $29.64. 377,738 shares changed hands during trading, a decline of 59% from the average session volume of 912,665 shares. The stock had previously closed at $26.88.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on MTSR shares. Wells Fargo & Company assumed coverage on Metsera in a research note on Friday, June 20th. They issued an "overweight" rating and a $65.00 price target on the stock. Guggenheim lifted their price target on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research note on Tuesday, June 10th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $55.00.
Get Our Latest Research Report on Metsera
Metsera Stock Performance
The business's fifty day moving average is $27.09.
Metsera (NASDAQ:MTSR - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($1.03) earnings per share for the quarter.
Institutional Investors Weigh In On Metsera
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Alphabet Inc. bought a new stake in shares of Metsera in the 1st quarter valued at about $135,059,000. T. Rowe Price Investment Management Inc. purchased a new position in shares of Metsera during the first quarter worth $78,748,000. Wellington Management Group LLP acquired a new position in Metsera during the first quarter valued at $65,382,000. Alpha Wave Global LP purchased a new stake in Metsera in the first quarter valued at $64,894,000. Finally, Price T Rowe Associates Inc. MD acquired a new stake in Metsera during the 1st quarter worth about $42,395,000.
Metsera Company Profile
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Stories
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
